Literature DB >> 6489403

Cerebrospinal fluid neurophysins in affective illness and in schizophrenia.

P Linkowski, V Geenen, M Kerkhofs, J Mendlewicz, J J Legros.   

Abstract

We studied the concentration of neurophysin I (hNPI) and II (hNPII), the hypothalamo-pituitary carriers of vasopressin and oxytocin, in CSF of depressed and schizophrenic patients and age matched controls. Mean hNPI values were lower and mean hNPII values greater in schizophrenics than in controls. Lower hNPI values were observed in unipolar patients than in controls. In bipolar patients however, higher hNPI values were present. Significantly higher hNPII values were observed in bipolar patients than in controls; no difference was present between unipolars and controls. A positive correlation was observed with age in controls and bipolars for hNPII. These data emphasize the interest of studying the neurohypophysal function in affective illness and in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489403     DOI: 10.1007/bf00461555

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  26 in total

1.  Behavioral effects of intraventricularly administered vasopressin and vasopressin fragments.

Authors:  D de Wied
Journal:  Life Sci       Date:  1976-09-01       Impact factor: 5.037

2.  Desmopressin in post-traumatic amnesia.

Authors:  J S Jenkins; H M Mather; A K Coughlan; D G Jenkins
Journal:  Lancet       Date:  1979-12-08       Impact factor: 79.321

3.  Identification of a vasopressin-neurophysin and of an oxytocin-neurophysin in man.

Authors:  J J Legros; F Louis
Journal:  Neuroendocrinology       Date:  1974       Impact factor: 4.914

4.  Vasopressin in amnesia.

Authors:  D R Blake; M J Dodd; J G Evans
Journal:  Lancet       Date:  1978-03-18       Impact factor: 79.321

5.  Vasopressin exhibits a rhythmic daily pattern in cerebrospinal fluid but not in blood.

Authors:  S M Reppert; H G Artman; S Swaminathan; D A Fisher
Journal:  Science       Date:  1981-09-11       Impact factor: 47.728

6.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

7.  Platelet vasopressin receptors in bipolar affective illness.

Authors:  W H Berrettini; J I Nurnberger; E K Worthington; S Simmons-Alling; E S Gershon
Journal:  Psychiatry Res       Date:  1982-08       Impact factor: 3.222

8.  An inability of subcutaneous vasopressin to affect passive avoidance behavior.

Authors:  G Hostetter; S L Jubb; G P Kozlowski
Journal:  Neuroendocrinology       Date:  1980       Impact factor: 4.914

9.  Dopaminergic control of oxytocin release in lactating rats.

Authors:  G Clarke; D W Lincoln; L P Merrick
Journal:  J Endocrinol       Date:  1979-12       Impact factor: 4.286

10.  Vasopressin in affective illness.

Authors:  P W Gold; F K Goodwin; V I Reus
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

View more
  22 in total

Review 1.  The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings.

Authors:  David M Cochran; Daniel Fallon; Michael Hill; Jean A Frazier
Journal:  Harv Rev Psychiatry       Date:  2013 Sep-Oct       Impact factor: 3.732

2.  Sexual differentiation of vasopressin innervation of the brain: cell death versus phenotypic differentiation.

Authors:  Geert J de Vries; Michelle Jardon; Mohammed Reza; Greta J Rosen; Eleanor Immerman; Nancy G Forger
Journal:  Endocrinology       Date:  2008-05-22       Impact factor: 4.736

3.  Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

Authors:  Kai Macdonald; David Feifel
Journal:  Acta Neuropsychiatr       Date:  2011-12-19       Impact factor: 3.403

4.  Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders.

Authors:  Leah H Rubin; C Sue Carter; Jeffrey R Bishop; Hossein Pournajafi-Nazarloo; Lauren L Drogos; S Kristian Hill; Anthony C Ruocco; Sarah K Keedy; James L Reilly; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga; Elliot S Gershon; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-03-11       Impact factor: 9.306

Review 5.  Promise and pitfalls of animal models of schizophrenia.

Authors:  David Feifel; Paul D Shilling
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

6.  Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.

Authors:  Mary R Lee; Heidi J Wehring; Robert P McMahon; Fang Liu; Jared Linthicum; Joseph G Verbalis; Robert W Buchanan; Gregory P Strauss; Leah H Rubin; Deanna L Kelly
Journal:  Schizophr Res       Date:  2016-02-12       Impact factor: 4.939

7.  The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating.

Authors:  David Feifel; Paul D Shilling; Annabelle M Belcher
Journal:  Eur Neuropsychopharmacol       Date:  2011-10-01       Impact factor: 4.600

Review 8.  Potential of Oxytocin in the Treatment of Schizophrenia.

Authors:  Paul D Shilling; David Feifel
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

9.  Sex and diagnosis specific associations between DNA methylation of the oxytocin receptor gene with emotion processing and temporal-limbic and prefrontal brain volumes in psychotic disorders.

Authors:  Leah H Rubin; Jessica J Connelly; James L Reilly; C Sue Carter; Lauren L Drogos; Hossein Pournajafi-Nazarloo; Anthony C Ruocco; Sarah K Keedy; Ian Matthew; Neeraj Tandon; Godfrey D Pearlson; Brett A Clementz; Carol A Tamminga; Elliot S Gershon; Matcheri S Keshavan; Jeffrey R Bishop; John A Sweeney
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2015-11-09

10.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.